89BIO INC. - COMMON S

89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

24 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors

24 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference

09 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

24 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume 

14 Nov 2021 18:30:00 By Nasdaq GlobeNewswire

89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

11 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

89bio Announces Appointment of Kathy LaPorte to its Board of Directors

03 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021

25 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the Cantor Global Healthcare Conference

21 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

08 Sep 2021 16:15:00 By Nasdaq GlobeNewswire

89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

12 Aug 2021 16:05:01 By Nasdaq GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

03 Aug 2021 16:15:00 By Nasdaq GlobeNewswire

89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH

02 Aug 2021 08:30:00 By Nasdaq GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

16 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH

10 Jun 2021 08:30:00 By Nasdaq GlobeNewswire

89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

12 May 2021 16:05:00 By Nasdaq GlobeNewswire

89bio to Present at Upcoming Investor Conferences

05 May 2021 08:00:01 By Nasdaq GlobeNewswire

89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH

05 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

24 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference

20 Mar 2021 11:00:00 By Nasdaq GlobeNewswire